Compare Incyte Corporation (INCY) vs T-Rex 2X Long MSTR Daily Target ETF (MSTU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs T-Rex 2X Long MSTR Daily Target ETF — how do they compare? Incyte Corporation trades at $112.79 (market cap $22.85B), while T-Rex 2X Long MSTR Daily Target ETF trades at $39.7 (market cap $809.00M). The key difference: Incyte Corporation is far larger — about 28.2× T-Rex 2X Long MSTR Daily Target ETF's market cap, and Incyte Corporation is trading nearer its 52-week high, T-Rex 2X Long MSTR Daily Target ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Incyte Corporation for 33 Days and T-Rex 2X Long MSTR Daily Target ETF for 18 Days on average.
| INCY | MSTU | |
|---|---|---|
Market Cap | $22.85B | $809.00M |
Volume | 1,927,029 | 4,577,465 |
Sector | Health | Leveraged / Inverse |
52-Week High | $129.93 | $432.00 |
52-Week Low | $83.80 | $14.60 |
Typical Hold Time | 33 Days | 18 Days |
Enterprise Value | $18.35B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte (INCY) trades at $112.75, down 0.61% on the day, with a bearish technical signal despite strong fundamentals. The company reported robust 2025 results with $5.14B revenue and $1.29B net income, showing significant margin expansion. Recent FDA approval for Atebrioz and pipeline progress support growth prospects beyond JAKAFI's 2029 exclusivity loss. Analyst consensus is bullish with a $132.43 price target, though technical indicators show selling pressure near key resistance.
Outlook remains positive driven by pipeline diversification and operational leverage, but near-term technical weakness and reliance on JAKAFI transition pose risks. The stock offers value with a 14.36 P/E ratio and strong profitability metrics, though investors should monitor execution on the $4B non-JAKAFI sales target and quarterly earnings consistency.
MSTU is trading at $38.33, down 2.84% on the day, with a bearish technical outlook as moving averages signal selling pressure. The stock recently underwent a 10:1 reverse stock split effective August 24, 2026, and declared a $0.29 dividend payable August 26, 2026. Key support levels are at $37 and $35, while resistance sits at $40 and $41.
The outlook remains cautious due to the bearish technical setup and lack of current fundamental data. Investment opportunities hinge on the company's ability to demonstrate improved financial performance post-reverse split, while risks include continued technical weakness and potential volatility from the leveraged ETF structure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About T-Rex 2X Long MSTR Daily Target ETF
MSTU is a leveraged ETF that seeks daily investment results corresponding to 200% of the daily performance of the MicroStrategy Incorporated (MSTR) stock. It is designed as a tactical tool for experienced traders to take a bullish (long) position in MSTR, a company known for its significant Bitcoin holdings. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment.
Read more on MSTU →
